Specifically for NSCLC, anti‐PD1 or anti‐PD‐L1 antibodies are used building on the premise that by inhibiting the interaction between programmed cell death protein 1 (PD‐1) receptor expressed on activated T cells and PD‐L1 expressed in tumor cells that exhausted cytotoxic CD8+ T cells could be reinvigorated and elicit an effective antitumor response from the host's adaptive immune system.1 Here, PDCD1 is linked to non-small cell lung carcinoma.